Abstract
An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would...Continue Reading
References
Jan 13, 2010·MAbs·Adith Venkiteshwaran
Apr 21, 2010·Nature Immunology·Taro Kawai, Shizuo Akira
Oct 1, 2010·Therapeutic Advances in Musculoskeletal Disease·Srinivasan Srirangan, Ernest H Choy
Dec 12, 2012·Therapeutic Advances in Musculoskeletal Disease·Shumpei YokotaTadamitsu Kishimoto
May 20, 2014·Annals of the Rheumatic Diseases·Hermine I BrunnerUNKNOWN Pediatric Rheumatology Collaborative Study Group (PRCSG)
Jan 28, 2020·Lancet·Chaolin HuangBin Cao
Feb 6, 2020·Nature·Peng ZhouZheng-Li Shi
Feb 23, 2020·The Lancet. Respiratory Medicine·Zhe XuFu-Sheng Wang
Feb 25, 2020·JAMA : the Journal of the American Medical Association·Zunyou Wu, Jennifer M McGoogan
Mar 13, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chuan QinDai-Shi Tian
Mar 15, 2020·Lancet·Fei ZhouBin Cao
Mar 20, 2020·Cell & Bioscience·Kit-San YuenDong-Yan Jin
Mar 21, 2020·Lancet·Puja MehtaUNKNOWN HLH Across Speciality Collaboration, UK
Mar 29, 2020·JAMA : the Journal of the American Medical Association·Chenguang ShenLei Liu
Apr 8, 2020·Journal of Medical Virology·Pan LuoJuan Li